Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    evonik-m-2025-09-08

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Menu

    Belumosudil Mesylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 7,391Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 2Sanofi-Aventis Canada Inc.

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    PharmaCompass
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Sanofi-Aventis Canada Inc.

    BELUMOSUDIL MESYLATE
    arrow
    ChemOutsourcing
    Not Confirmed

    Sanofi-Aventis Canada Inc.

    Country
    arrow
    ChemOutsourcing
    Not Confirmed

    Patent Expiration Date : 2026-03-27

    Date Granted : 2015-03-24

    BELUMOSUDIL MESYLATE

    Brand Name : REZUROCK

    Patent Number : 2602254

    Filing Date : 2006-03-27

    Strength per Unit : 200 mg

    Dosage Form : TABLET

    Human Or VET : Human

    Route of Administration : ORAL

    Patent Expiration Date : 2026-03-27

    Date Granted : 2015-03-24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Sanofi-Aventis Canada Inc.

    BELUMOSUDIL MESYLATE
    arrow
    ChemOutsourcing
    Not Confirmed

    Sanofi-Aventis Canada Inc.

    Country
    arrow
    ChemOutsourcing
    Not Confirmed

    Patent Expiration Date : 2033-10-07

    Date Granted : 2022-05-24

    BELUMOSUDIL MESYLATE

    Brand Name : REZUROCK

    Patent Number : 2926478

    Filing Date : 2013-10-07

    Strength per Unit : 200 mg

    Dosage Form : TABLET

    Human Or VET : Human

    Route of Administration : ORAL

    Patent Expiration Date : 2033-10-07

    Date Granted : 2022-05-24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF